Evidence map›Paper›PMID 34242218›Full record

ArticlePloS one2021

Implementation of the Ebola Virus Persistence in Ocular Tissues and Fluids (EVICT) study: Lessons learned for vision health systems strengthening in Sierra Leone.

Jessica G Shantha, Ian Crozier, Colleen S Kraft, Donald G Grant, Augustine Goba, Brent R Hayek, Caleb Hartley, Kayla G Barnes, Timothy M Uyeki, John Schieffelin and 7 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 9 institutions in 3 countries.

Jessica G ShanthaEmory Eye Center, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Ian CrozierNational Institute for Allergy and Infectious Disease, Bethesda, Maryland, United States of America.
Colleen S KraftDepartment of Pathology and Laboratory Medicine, Emory University Serious Communicable Disease Unit, Atlanta, Georgia, United States of America.
Donald G GrantKenema Government Hospital Lassa Hemorrhagic Fever Laboratory, Kenema, Sierra Leone.
Augustine GobaKenema Government Hospital Lassa Hemorrhagic Fever Laboratory, Kenema, Sierra Leone.
Brent R HayekEmory Eye Center, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Caleb HartleyEmory Eye Center, Emory University School of Medicine, Atlanta, Georgia, United States of America.ORCID 0000-0002-8259-2518
Kayla G BarnesDepartment of Organismic and Evolutionary Biology, Harvard University, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America.
Timothy M UyekiCenters for Disease Control and Prevention, Atlanta, Georgia, United States of America.
John SchieffelinTulane University School of Medicine, New Orleans, Louisiana, United States of America.
Robert F GarryTulane University School of Medicine, New Orleans, Louisiana, United States of America.
Daniel G BauschUnited Kingdom Public Health Rapid Support Team (UK-PHRST), London School of Tropical Medicine and Hygiene, Public Health England, London, United Kingdom.
Paul E FarmerPartners in Health, Boston, Massachusetts, United States of America.
John G MattiaLowell and Ruth Gess Eye Hospital, Freetown, Sierra Leone.
Matthew J VandyMinistry of Health and Sanitation, National Eye Programme, Freetown, Sierra Leone.
Steven YehEmory Eye Center, Emory University School of Medicine, Atlanta, Georgia, United States of America.ORCID 0000-0002-5417-7771
EVICT Study Investigators
Emory University · USTulane University · USBroad Institute · USCenters for Disease Control and Prevention · USMinistry of Health and Sanitation · SLNational Institute of Allergy and Infectious Diseases · USPartners In Health · USPublic Health England · GBSierra Leone Urban Research Centre · SL

Funding

P30-Core Grant for Vision Research Core CP30EY006360 · NEI · EMORY UNIVERSITY · PI NICKERSON, JOHN M · 1986 to 2025
$15.3M
Pathogenesis of Uveitis in Ebola Virus Disease SurvivorsR01EY029594 · NEI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI YEH, STEVEN · 2019 to 2023
$2.9M
Ophthalmic Disease and Laboratory Surveillance in a Viral Hemorrhagic Fever ZoneK23EY030158 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SHANTHA, JESSICA · 2019 to 2023
$1.2M
NEI NIH HHS K23 EY030158NEI NIH HHS P30 EY006360NEI NIH HHS R01 EY029594
6 · The paper itself

Abstract

backgroundFollowing the West African Ebola virus disease (EVD) outbreak of 2013-2016 and more recent EVD outbreaks in the Democratic Republic of Congo, thousands of EVD survivors are at-risk for sequelae including uveitis, which can lead to unremitting inflammation and vision loss from cataract. Because of the known risk of Ebola virus persistence in ocular fluid and the need to provide vision-restorative, safe cataract surgery, the Ebola Virus Persistence in Ocular Tissues and Fluids (EVICT) Study was implemented in Sierra Leone. During implementation of this multi-national study, challenges included regulatory approvals, mobilization, community engagement, infection prevention and control, and collaboration between multiple disciplines. In this report, we address the multifacted approach to address these challenges and the impact of implementation science research to address an urgent clinical subspecialty need in an outbreak setting. METHODOLOGY/PRINCIPAL

findingsGiven the patient care need to develop a protocol to evaluate ocular fluid for Ebola virus RNA persistence prior to cataract surgery, as well as protocols to provide reassurance to ophthalmologists caring for EVD survivors with cataracts, the EVICT study was designed and implemented through the work of the Ministry of Health, Sierra Leone National Eye Programme, and international partnerships. The EVICT study showed that all 50 patients who underwent ocular fluid sampling at 19 and 34 months, respectively, tested negative for Ebola virus RNA. Thirty-four patients underwent successful cataract surgery with visual acuity improvement. Here we describe the methodology for study implementation, challenges encountered, and key issues that impacted EVD vision care in the immediate aftermath of the EVD outbreak. Key aspects of the EVICT study included defining the pertinent questions and clinical need, partnership alignment with key stakeholders, community engagement with EVD survivor associations, in-country and international regulatory approvals, study site design for infection prevention and control, and thorough plans for EVD survivor follow-up care and monitoring. Challenges encountered included patient mobilization owing to transportation routes and distance of patients in rural districts. Strong in-country partnerships and multiple international organizations overcame these challenges so that lessons learned could be applied for future EVD outbreaks in West and Central Africa including EVD outbreaks that are ongoing in Guinea and Democratic Republic of Congo. CONCLUSIONS/SIGNIFICANCE: The EVICT Study showed that cataract surgery with a protocol-driven approach was safe and vision-restorative for EVD survivors, which provided guidance for EVD ophthalmic surgical care. Ophthalmologic care remains a key aspect of the public health response for EVD outbreaks but requires a meticulous, yet partnered approach with international and local in-country partners. Future efforts may build on this framework for clinical care and to improve our understanding of ophthalmic sequelae, develop treatment paradigms for EVD survivors, and strengthen vision health systems in resource-limited settings.

Indexed as

EbolavirusHemorrhagic Fever, EbolaBody FluidsCataractCataract ExtractionDisease OutbreaksEyeFemaleHumansMaleRNA, ViralSierra LeoneRNA, Viral

Identifiers

PMID34242218
PMCPMC8270115
OpenAlexW3180424556

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.